PharmaEssentia is a global biopharmaceutical company delivering efficacious, safe and cost-effective therapeutic products for the treatment of myeloproliferative neoplasms (MPNs) such as polycythemia vera (PV), essential thrombocythemia (ET), chronic myeloid leukemia, hepatitis, and other diseases. PharmaEssentia is developing ropeginterferon alfa-2b, a novel, long-acting, mono-pegylated proline interferon for both PV and ET. It is uniquely administered once every two weeks, offering improved tolerability and convenience, and may offer the potential for disease modification. A Phase III clinical trial for ropeginterferon alfa-2b in PV was recently completed, and the company plans to present data to the U.S. FDA for approval. If approved, ropeginterferon alfa-2b is expected to be the first interferon approved for PV worldwide and the only approved first-line treatment for PV in the U.S.http://www.pharmaessentia.com/ or http://www.ropeginf.com/
